Akari Therapeutics, Plc – NASDAQ:AKTX

Add to watchlist

+0.03

+3.28%

Market closed

Open in about 14 hours

-72.34%

month

-72.34%

quarter

-69.17%

year

Market Cap	11.78M
Enterprise value	N/A

P/E	-0.61
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	1.30
PEG ratio	-0.02
EPS	-2.81

Revenue	N/A
EBITDA	-28.94M
Income	-15.57M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Akari Therapeutics, Plc (NASDAQ:AKTX): Profit margin
Jun 2023	0	-2.99M
Sep 2023	0	-3.50M
Dec 2023	0	-3.50M
Mar 2024	0	-5.56M

Akari Therapeutics Financials Estimate

Q Y

Akari Therapeutics, Plc (NASDAQ:AKTX): Analyst Estimates
2025	3.54M	-32.27M	-911.32%
2026	9.58M	0

Analysts Price target
Financials & Ratios estimates

Akari Therapeutics, Plc (NASDAQ:AKTX): Debt to assets
Jun 2023	8012971	5.23M	65.29%
Sep 2023	4355000	4.58M	105.26%
Dec 2023	4355000	4.58M	105.26%
Mar 2024	2772000	6.32M	228.17%

Akari Therapeutics, Plc (NASDAQ:AKTX): Cash Flow
Jun 2023	-9.56M	3.49M
Sep 2023	-3.42K	1.75K
Dec 2023	-3.42K	1.75K
Mar 2024	-4.04M	1.51M

Akari Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Akari Therapeutics, Plc (NASDAQ:AKTX): Employee count
Aug 2023	15
Sep 2023	15
Oct 2023	15
Nov 2023	15
Dec 2023	15
Jan 2024	15
Feb 2024	15
Mar 2024	15
Apr 2024	15
May 2024	9
Jun 2024	9
Jul 2024	9

Akari Therapeutics
Hedge Funds Holdings Q1 2023

0.02% -0.13%

of AKTX is owned by hedge funds

7 -8

hedge funds hold AKTX stock

1.43M -7.48M

shares is hold by hedge funds

AKTX hedge funds holdings changes

Akari Therapeutics
Insider Trading

Akari Therapeutics, Plc (NASDAQ:AKTX): Insider trades (number of shares)
Period	Buy	Sel
Sep 2015	1055600	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	18 Sep 2015	COHEN MARK S director director	Ordinary Shares	1,055,600	$0.19	$200,564
Purchase	15 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	17,100	$5	$85,500
Purchase	14 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	3,000	$5.21	$15,630
Purchase	11 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	100	$5.15	$515
Purchase	10 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	1,400	$5.25	$7,350
Purchase	9 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	1,075	$5.51	$5,923
Purchase	8 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	35,500	$5.36	$190,280
Purchase	7 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	20,654	$5.82	$120,206
Purchase	4 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	12,250	$6.04	$73,990
Purchase	2 Apr 2014	SABBY MANAGEMENT, LLC 10 percent owner 10 percent owner	Common stock	2,500	$6.15	$15,375

AKTX insider trading transactions

Akari Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q4 2017 21 Mar 2018	Q4 2017 Earnings Call Transcript

AKTX earnings call transcripts

Akari Therapeutics
Executives

Insider	Age	Compensation
Mr. Clive Richardson (1965) Chief Operating Officer, Chief Executive Officer & Director	60	$780,940
Dr. Ray Prudo-Chlebosz M.D. (1945) Executive Chairman	80	$618,000
Dr. Torsten Hombeck (1970) Chief Financial Officer	55	$309,860

Akari Therapeutics
Latest News

Wednesday, 18 December 2024
08:51	Akari Therapeutics Announces Key Leadership Appointments	globenewswire.com
Monday, 16 December 2024
09:05	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer	globenewswire.com
Thursday, 14 November 2024
16:15	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio	globenewswire.com
Friday, 8 November 2024
08:00	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger	globenewswire.com
Friday, 11 October 2024
18:45	SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO	accesswire.com
Monday, 19 August 2024
16:15	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights	globenewswire.com
08:00	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy	globenewswire.com
Thursday, 16 May 2024
08:00	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights	globenewswire.com
Wednesday, 1 May 2024
08:01	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics	globenewswire.com
08:00	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity	globenewswire.com
Monday, 15 April 2024
08:00	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024	GlobeNewsWire
Thursday, 14 December 2023
08:00	Akari Therapeutics to Present at Biotech Showcase 2024	GlobeNewsWire
Monday, 6 November 2023
08:00	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference	GlobeNewsWire
Wednesday, 27 September 2023
08:00	Akari Therapeutics to Present at Emerging Growth Conference	GlobeNewsWire
Friday, 28 July 2023
11:59	Best Penny Stocks To Buy? 6 To Watch Before Next Week	PennyStocks
Thursday, 27 July 2023
17:34	Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down	PennyStocks
Wednesday, 4 January 2023
08:00	Akari Therapeutics to Present at Biotech Showcase™ 2023	GlobeNewsWire
Tuesday, 13 September 2022
05:58	Akari Therapeutics (AKTX) Stock: Why It 27.88%	Pulse2
Wednesday, 11 May 2022
07:00	Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting	GlobeNewsWire
Friday, 11 February 2022
07:00	Akari Therapeutics to Present at BIO CEO & Investor Conference	GlobeNewsWire
Tuesday, 4 January 2022
07:00	Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference	GlobeNewsWire
Friday, 31 December 2021
08:59	Akari Therapeutics Stock (AKTX): Why The Price Fell	Pulse2
Wednesday, 22 September 2021
08:30	Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress	GlobeNewsWire
Friday, 10 September 2021
08:30	Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium	GlobeNewsWire
Tuesday, 7 September 2021
07:00	Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Akari Therapeutics stock today?

One share of Akari Therapeutics stock can currently be purchased for approximately $1.
When is Akari Therapeutics's next earnings date?

Unfortunately, Akari Therapeutics's (AKTX) next earnings date is currently unknown.
Does Akari Therapeutics pay dividends?

No, Akari Therapeutics does not pay dividends.
How much money does Akari Therapeutics make?

Akari Therapeutics has a market capitalization of 11.78M.
What is Akari Therapeutics's stock symbol?

Akari Therapeutics, Plc is traded on the NASDAQ under the ticker symbol "AKTX".
What is Akari Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Akari Therapeutics?

Shares of Akari Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Akari Therapeutics's key executives?
Akari Therapeutics's management team includes the following people:
- Mr. Clive Richardson Chief Operating Officer, Chief Executive Officer & Director(age: 60, pay: $780,940)
- Dr. Ray Prudo-Chlebosz M.D. Executive Chairman(age: 80, pay: $618,000)
- Dr. Torsten Hombeck Chief Financial Officer(age: 55, pay: $309,860)
How many employees does Akari Therapeutics have?

As Jul 2024, Akari Therapeutics employs 9 workers, which is 40% less then previous quarter.
When Akari Therapeutics went public?

Akari Therapeutics, Plc is publicly traded company for more then 11 years since IPO on 6 Jan 2014.
What is Akari Therapeutics's official website?

The official website for Akari Therapeutics is akaritx.com.
How can i contact Akari Therapeutics?

Akari Therapeutics can be reached via phone at +44 20 8004 0270.

Akari Therapeutics, Plc

akaritx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

+44 20 8004 0270

75/76 Wimpole Street
London, W1G 9RT

CIK: 0001541157
ISIN: US00972G2075
CUSIP: 00972G108